UBS AM’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

UBS AM’s Portfolio ANAC Stock Details ANAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-51,347	Closed	-$2.74M	–	2693
2016 Q1	$2.74M	Sell	51,347 -12,405	-19%	-$916K	﹤0.01%	1233
2015 Q4	$7.2M	Sell	63,752 -2,154	-3%	-$237K	0.01%	950
2015 Q3	$7.76M	Buy	65,906 +42,406	+180%	+$5.54M	0.01%	926
2015 Q2	$1.82M	Buy	23,500 +3,500	+18%	+$229K	﹤0.01%	1443
2015 Q1	$1.16M	Buy	20,000 +8,500	+74%	+$361K	﹤0.01%	1577
2014 Q4	$371K	Buy	11,500 +1,300	+13%	+$39K	﹤0.01%	2101
2014 Q3	$250K	Buy	+10,200	New	+$207K	﹤0.01%	2251

Other funds holding ANAC

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

UBS AM's ANAC Position: Q2 2016 in Review

UBS AM sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 51,347 shares — an estimated $2.74M sold.

UBS AM first reported a position in ANAC in Q3 2014 and held it in 7 quarters. The position peaked at $7.76M in Q3 2015. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

UBS AM reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
UBS AM sold 51,347 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $2.74M.
UBS AM first reported a position in ANACOR PHARMACEUTICALS INC COM in Q3 2014 and held it in 7 quarters.
UBS AM's ANACOR PHARMACEUTICALS INC COM position peaked at $7.76M in Q3 2015.
2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on UBS AM's 13F filing for Q2 2016, filed 9 Aug 2016.